We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ABVC BioPharma Inc (ABVC) USD0.001

Sell:$2.59 Buy:$2.69 Change: $0.25 (10.16%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.25 (10.16%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Change: $0.25 (10.16%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ABVC BioPharma, Inc. (ABVC), formerly American BriVision (Holding) Corporation, is a biotechnology company focused on the development of drugs and medical devices. The Company is focused on developing its pipeline by tracking medical discoveries or medical device technologies in research institutions. ABVC has approximately six drugs and three medical devices in development. The Company's pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1702, ABV-1703, ABV-1601, ABV-1701, ABV-2001 and ABV-2002. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine. ABVC is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). ABV-1702 is to treat myelodysplastic syndromes (MDS). ABVC developed an indication, ABV-1703, for Pancreatic Cancer. The Company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy.

Contact details

44370 Old Warm Springs Blvd
United States
+1 (510) 6680881

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$57.51 million
Shares in issue:
24.47 million
No specific industry
United States
US dollar

Key personnel

  • Eugene Jiang
    Chairman of the Board, Chief Business Officer
  • Howard Doong
    Chief Executive Officer
  • Chihliang An
    Chief Financial Officer
  • Chi-Hsin King
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.